Loading...
•
Jun 30, 2020
BeiGene Q2 2020 Earnings Report
BeiGene's product sales increased driven by recently launched internally developed products.
Key Takeaways
BeiGene reported a product revenue increase of 13% compared to the same period last year, reaching $65.64 million. The company raised net proceeds of approximately $2.07 billion through a registered direct offering.
Received approval from the NMPA for BRUKINSA in China for the treatment of adult patients with CLL/SLL and MCL.
Received approval from the NMPA and launched tislelizumab in China for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma.
Began commercializing XGEVA in China for the treatment of giant cell tumor of bone.
Generated $65.64 million in product revenue, representing a 13% increase compared to the comparable period of the prior year.
Revenue by Segment
Forward Guidance
BeiGene expects the COVID-19 pandemic to continue to have a negative impact on its operations, including commercial sales, regulatory interactions and inspections, and clinical trial recruitment and participation. The Company is striving to minimize delays and disruptions, and continues to execute on its commercialization, regulatory and clinical development goals globally.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...